Skip to NavigationSkip to content

Gilead

Long-term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

Published on: 07/06/19

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.

In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.

Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.

Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.

In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.

Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.

Top Ten most popular articles on Pharmafile.com this week

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week's biggest stories in the pharmaceutical industry.

Top Ten most popular articles on Pharmafile.com this week!

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate lawsuits accused them and others of suppressing competition. While Gilead had sought to retain dominance in the HIV drugs market, Teva was alleged to be at the centre of a conspiracy through which generic drugmakers divided up the market for generic meds.

Gilead CEO Daniel O'Day challenged over patents on PrEP drug Truvada

Image Credit: nrkbeta

On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a US congressional hearing. At a cost of more than $21,000 a year, the preventative-HIV drug is 222 times more expensive in the US than it is in Australia, where it costs just $8.

Explaining the price discrepancy, O’Day said: “Truvada still has patent protection in the United States, and in the rest of the world it is generic. It will be generically available in the United States as of September 2020.”

Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says

Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for HIV drugs, according to a lawsuit filed by AIDS activists and unions.

The California firm colluded with BMS and J&J – whose medicines were used in a drug combination cocktail – to prevent generic competition, the lawsuit says.

The lawsuit alleges the two companies agreed to only use Gilead’s version of tenofovir, even after Gilead’s patent had expired.

Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after 'discussions' with Trump

Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions between the Trump Administration” and the California firm.

Gilead Sciences will give preventative HIV drug Truvada to uninsured individuals who are at risk of being infected with HIV, Health and Human Services Secretary Alex Azar said.

The agreement will last until at least the end of 2025 and may continue through to December 31 2030.

Gilead's CFO and Executive Vice President to depart in 2020

Published on: 07/05/19

Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, has stepped down from her role.

Washington joined the company in 2008 as CFO, and was promoted to Executive Vice President in 2014. In her role, she oversees Gilead’s Global Finance and Information Technology organisations.

Top Ten most popular articles on Pharmafile.com this week!

This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from poor results in late stage studies. Lilly’s failure was so such that they decided to withdraw Latruvo from the market.

Gilead's CFO and Executive Vice President to depart in 2020

Image credit: Gilead, Associated Press

Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, is set to step down from her role effective 1 March 2020.

Washington joined the company in 2008 as CFO, and was promoted to Executive Vice President in 2014. In her role, she oversees Gilead’s Global Finance and Information Technology organisations.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches